au·de·re /ˈôdəˌrā/
verb, Latin (audo, audeo, audere)
dare, venture, act boldly, risk
intend, be prepared
Audere is a global digital health nonprofit developing HealthPulse™ solutions to advance health equity in underserved communities worldwide. We operate at the unique intersection of global health and high tech, creating advanced, accessible software that revolutionizes the detection and treatment of diseases — such as malaria, COVID-19, and HIV. Our diverse team of passionate, innovative minds combines smartphone technology, artificial intelligence, and the best of cloud-based services to deliver HealthPulse™ solutions worldwide. Development of our projects is funded by grants and support from the Bill & Melinda Gates Foundation, FIND, and other global health partners.
Check out our Company Overview to learn more about our projects and partnerships.
Our Projects
Diagnostic Aides
worldwide
412 million rapid diagnostic tests (RDTs) are administered worldwide each year for malaria, of which tens of millions are either incorrectly administered or misinterpreted. We have developed software that improves the accuracy of rapid diagnostic test administration and interpretation — supporting community health workers through HealthPulse DxA™. Our solution reduces RDT administration errors below 2% and reduces interpretation error rates below 1.6%, even identifying faint positive result lines better than experts.
More about this project >
Clinicians, community health workers, and patients can access the flexible functionality as an offline-capable app or web-based solution, seamlessly fitting into existing tools and workflows. Designed to support any RDT for any health condition, HealthPulse DxA scales to meet unique challenges in disease surveillance, management, and eradication. HealthPulse DxA was piloted in Nigeria and Kenya to support malaria studies.
We are also working with partners to provide HIV testing, treatment, and prevention solutions in Kenya and South Africa. Lastly, we collaborate with partners who are developing similar RDT solutions for tuberculosis and other communicable diseases relevant to global health.
COVID-19
Worldwide
The first case of COVID-19 in the U.S. was confirmed on January 20, 2020 in Washington state. When cases started to spread from our backyard across the nation, we felt a call to action and immediately began designing HealthPulse@home™ COVID-19 Specimen Collection Test Kits and instructions for lower nasal swab self-collection that could support communities in the fight against coronavirus. We also created a COVID-19 symptom tracking and surveillance tool for the Seattle Fire Department. Years into the pandemic, the U.S. continues to struggle with testing availability and accessibility when surges occur.
More about this project >
We translated our experience conducting flu studies with self-swab kits to develop an at-home, self-swab COVID-19 test kit, HealthPulse@home, which has been authorized by the FDA for Emergency Use. Using Audere’s authorized labeling instructions, CLIA-certified laboratories can customize and rebrand HealthPulse@home to bring their own self-collection COVID-19 specimen kits to market without individually completing all of the steps required to obtain an FDA Emergency Use Authorization (EUA). Increasing the availability of self-testing and reducing the burden on the healthcare system will help lower continued community spread of coronavirus.
Audere received the 2020 Justworks Spring Forward Fund grant to develop technology that aids COVID-19 rapid testing. For an inside look at Audere’s journey through the early days of the pandemic, check out this video.
HIV Studies
Africa
Oral, once-daily Pre-Exposure Prophylaxis (PrEP) medicine is prescribed to patients at risk of contracting HIV, and when taken as prescribed, is up to 99% effective at preventing HIV from sex and up to 74% effective at preventing HIV from injection drug use. With 190 million people tested for HIV in 2018, there is considerable opportunity for PrEP therapies to prevent HIV in high-risk patient populations. We are participating in a study with Fred Hutchinson Cancer Research Center, Jhpiego, Jomo Kenyatta University of Agriculture and Technology, MYDAWA, and University of Washington to develop and evaluate an ePharmacy platform for HIV PrEP delivery in Kenya. Audere is developing a solution that aids consumers in the administration of HIV self-tests as well as AI interpretation of the test to aid a remote healthcare worker in interpreting the result.
Flu Studies
United States
Australia
In a single season, the flu can infect up to 56 million people in the United States alone, resulting in up to 62,000 deaths. The burden that this causes on the US healthcare system is significant: up to 26 million of those infected will seek medical guidance and up to 740,000 of them will be hospitalized. We developed the flu@home mobile app to walk consumers through self-administration of an at-home self-swab flu test, to help detect cases of the flu from home. Using AI algorithms, the app interprets the results of a user’s scanned test strip. Studies using flu@home were conducted in both the United States and Australia.
Pharma Claims
Africa
60% of East Africa’s primary healthcare is provided by small businesses that often lack the technology required to deliver effective care. By tracking incentive claims, a pharmacy can deliver better care for their community and provide discounts and subsidies to patients. We partnered with Maisha Meds to deliver a dashboard for pharmacy administrators in Kenya to review, approve, and pay out incentive claims.
Our Partners
Noteworthy News
